Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease
Franchimont, N. ; Putzeys, V. ; Collette, J. ; Vermeire, S. ; Rutgeerts, P. ; De Vos, M. ; Van Gossum, A. ; Franchimont, D. ; Fiasse, R. ; Pelckmans, P. ; Malaise, M. ; Belaiche, J. ; Louis, E.
Oxford, UK : Blackwell Science Ltd
Published 2004
Oxford, UK : Blackwell Science Ltd
Published 2004
| ISSN: |
1365-2036
|
|---|---|
| Source: |
Blackwell Publishing Journal Backfiles 1879-2005
|
| Topics: |
Medicine
|
| Notes: |
Background : Crohn's disease is associated with low bone mineral density and altered bone metabolism.Aim : To assess the evolution of bone metabolism in Crohn's disease patients treated with infliximab.Methods : We studied 71 Crohn's disease patients treated for the first time with infliximab for refractory Crohn's disease. Biochemical markers of bone formation (type-I procollagen N-terminal propeptide, bone-specific alkaline phosphatase, osteocalcin) and of bone resorption (C-telopeptide of type-I collagen) were measured in the serum before and 8 weeks after infliximab therapy and compared with values in a matched healthy control group.Results : Eight weeks after treatment with infliximab, a normalization of bone markers was observed with a median increase in formation markers of 14–51% according to marker and a lower but significant decrease in resorption marker (median 11%). A clinically relevant increase in bone formation markers was present in 30–61% of patients according to the marker. A clinically relevant decrease in C-telopeptide of type-I collagen was present in 38% of patients. No association was found with any tested demographic or clinical parameter.Conclusion : Infliximab therapy in Crohn's disease may rapidly influence bone metabolism by acting either on bone formation or bone resorption. This improvement seems to be independent of clinical response to infliximab.
|
| Type of Medium: |
Electronic Resource
|
| URL: |